New drug shows promise for childhood brain disease
A study from the University of Amsterdam has shown that a medication used to treat high blood pressure, called Guana Benz, may contribute to slowing the progression of a rare genetic white matter disease that affects children between the ages of 1 and 6. This condition leads to a loss of motor and cognitive abilities and often results in early death. The results indicated that children treated with Guana Benz relied less on wheelchairs and at a slower rate, with no deaths among treated children during the study period. Although side effects such as hallucinations, drowsiness, and low blood pressure appeared, their severity improved after several months. This is the first study to demonstrate the potential to affect this deadly disease, and research is ongoing to monitor the effects of higher doses and the long-term effectiveness of the treatment.
Notice: This Is an AI-Generated Summary
Comments (0)